PROK · Prokidney Corp.
$1.53
-0.07 (-4.08%)
At close · Jul 22
Market Cap
$462.15M
Shares
302.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.53
Open$1.59
Day$1.53–1.61
52W$1.53–3.55
Avg vol 30d1.3M
Short int19.4M · 6.4% float · 10.0d
Short vol85%
Last earningsMay 10, 2024
DataJun 2021–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−12%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−27%
trailing
YTD return
−32%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
3 of 71 funds reported for Jun 30 · net +259.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.43% of float · ▲ +10.7% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
71 holders — near 1-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+1075%
Y/Y
Free cash flow
$-135.3M
Balance sheet
$108.5M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
3 of 71 funds reported for Jun 30 · net +259.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.43% of float · ▲ +10.7% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
71 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $4
vs 200-day avg -29%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PROK
this stock
Prokidney Corp.
|
$462.15M | -31.7% | — | — | 6.4% |
|
ONC
BeOne Medicines Ltd.
|
$462.38B | +5.3% | +22179.2% | 941.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.94B | +4.2% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.27B | -15.5% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$53.28B | +1.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PROK | -4.4% | -15.0% | -27.1% | -25.0% | -31.7% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | -3.4% | -16.9% | -34.6% | -25.1% | -41.3% |